Abstract: Adalimumab and Infliximab are recombinant IgG1 monoclonal antibodies (mAbs) that bind and neutralize human tumor necrosis factor alpha (TNFa). TNFa forms a stable homotrimer with unique surface-exposed sites for Adalimumab, Infliximab, and TNF receptor binding. Here, we report the structures of Adalimumab-TNFa and Infliximab-TNFa complexes modeled from negative stain EM and cryo-EM images. EM images reveal complex structures consisting of 1:1, 1:2, 2:2, and 3:2 complexes of Adalimumab-TNFa and Infliximab-TNFa. The 2:2 complex structures of Adalimumab-TNFa and Infliximab-TNFa show diamond-shaped profiles and the 2D class averages reveal distinct orientations of the Fab domains, indicating different binding modes by Adalimumab and Infliximab to TNFa. After separation by size exclusion chromatography and analysis by negative stain EM, the 3:2 complexes of Adalimumab-TNFa or Infliximab-TNFa complexes are more complicated but retain features recognized in the 2:2 complexes. Preliminary cryo-EM analysis of 3:2 Adalimumab-TNFa complex generated a low-resolution density consistent with a TNFa trimer bound with three Fab domains from three individual antibody molecules, while each antibody molecule binds to two molecules of TNFa trimer. The Fc domains are not visible in the reconstruction. These results show the two mAbs form structurally distinct complexes with TNFa.
Introduction
TNFa is an important cytokine in regulating the inflammation and apoptosis pathways. Processed from a transmembrane protein through proteolytic cleavage by the metalloprotease, TNF alpha converting enzyme (TACE), 1 TNFa is released to form a compact bell-shaped trimer characterized by a 3-fold axis of symmetry. 2 Although biologically active as a homo-trimer, TNFa may dissociate to monomers at lower physiological concentrations. 3, 4 At elevated levels, TNFa can lead to development of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and inflammatory bowel diseases. These diseases are clinically treated by blocking TNFa binding to its receptors, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Different formats of biologics such as TNFR2-Fc recombinant fusion protein (Etanercept), monoclonal IgG1 antibodies (Adalimumab, Golimumab, and Infliximab), and PEGylated Fab' (Certolizumab) have proven effective in blocking TNFa cytokine activity.
Additional Supporting Information may be found in the online version of this article. Although the x-ray structures provided detailed structural insight into the interactions between the Fab domains of these antibodies with TNFa, the higher order complex structures formed between full-length antibodies and TNFa are not well understood. As TNFa and the anti-TNFa antibodies are both multivalent, it is highly plausible that antiTNFa antibodies may form higher order complex structures and aggregates with TNFa. The trimeric structure of TNFa provides three epitopes for Adalimumab or Infliximab, and their Fab domains binding to the trimer has been modeled in previous crystal structure studies. 7, 8 Full length Adalimumab and Infliximab have been shown to form higher order complexes with TNFa, with molecular weights as high as 4000 and 14,000 kDa, respectively. 6 Another report described a stable complex between Adalimumab (also known as D2E7) and TNFa of about 598 kDa that was formed upon overnight incubation at 378C. 9 Electron microscopy techniques have been successfully used to determine structures of monoclonal antibodies and other biologic molecules. Notably, EM structures have allowed us to understand the dynamics of the macromolecules and structural conformation upon formation of higher order complexes.
10-12 Individual-particle electron tomography (IPET) was utilized to demonstrate the flexibility and fluctuation of IgG1 antibody. 11 TEM studies on dual variable domain immunoglobulin (DVD-Ig) revealed the flexibility of the Fab and Fc regions, and the overall structure of its complex with two different antigens. 10 Here, we describe the structures of Adalimumab-TNFa and Infliximab-TNFa complexes deduced from negative stain TEM and cryo-EM techniques. EM imaging revealed AdalimumabTNFa and Infliximab-TNFa formed different and distinct higher order complexes through multivalent interactions. Our results will provide a structural basis for understanding the dynamics between TNFa and anti-TNFa antibodies.
Results

Structural analysis of Adalimumab and Infliximab alone
Adalimumab and Infliximab IgGs were negatively stained and imaged by TEM. In the images, the IgGs were distributed as well-separated particles and showing the distinct "Y" shape of an antibody with similar overall structures for both Adalimumab and Infliximab [ Fig. S1(A, B) ]. A population of particles was aligned, averaged, and clustered into common orientations by two-dimensional (2D) class averaging. As a result, two distinct domains for each Fab arm were clearly visible. In comparison, the Fc region adjacent to the Fab arms is less distinct and has lower intensity than the Fab arms [ Fig. 1 
(E,H)]
, which is also observed but less prominently in Adalimumab-TNFa (2:2). In addition to the appearance of the Fab arms, the dark center of the complex, also differs with cross and rectangular shapes, respectively, in the Infliximab-TNFa (2:2) and Adalimumab-TNFa (2:2) complexes [ Fig.  2(A,E) ]. These variations arise from different configurations of Fab arms when bound to TNFa in the 2:2 complexes.
Sub-tomographic averaging of AdalimumabTNFa (2:2) and Infliximab-TNFa (2:2) complex To reconstruct the 3D structure for AdalimumabTNFa (2:2) and Infliximab-TNFa (2:2) complexes, 120 and 198 particles from tilt-pair tomograms were selected, respectively. The reconstructed structures of these two complexes are low resolution and display a ring-like structure with two larger domains at opposite sides of the ring. These domains were assigned to two TNFa molecules due to the bellshaped structure of TNFa trimer. The Fc domain, which was indistinct in the 2D class averages, was not visible after sub-tomographic class averaging [ Fig. 2(B,F) ]. As a consequence of the low resolution tomography the Infliximab-TNFa (2:2) structure appears to be similar to Adalimumab-TNFa (2:2) and doesn't display the asymmetries seen in the projection images of the negatively stained complexes.
To further investigate the 2:2 complexes' structures, we compared their EM volumes with the 10Å X-ray model of Adalimumab-TNFa (2:2) and Infliximab-TNFa (2:2). This X-ray model was low pass filtered from 3WD5 and 4G3Y PDB structures using Chimera software. 7, 8 The X-ray models fitted well within the EM volumes [ Fig. 2(C,G) ]. X-ray model for Infliximab-TNFa (2:2) clearly showed the twisted arms located at two adjacent Fabs, while the twisted Fab arms on the 2:2 complex structures of Adalimumab-TNFa were positioned at opposite locations. The superimposed x-ray models on the EM volume of these two complexes, are consistent with the locations of TNFa, Fab, and Fc domains assigned in the 2D class averaged images.
EM of Adalimumab-TNFa (3:2) and InfliximabTNFa (3:2) complexes Fig. S2(A,D) ]. The fractions were used for negative stain EM analysis and further processing into 2D class averages [ Fig.  S2(B,E) ]. The Adalimumab-TNFa complex elutes from the SEC column, with molecular weight of approximately 600 kDa, in comparison to the calibration standards. Similarly Infliximab-TNFa elutes with a major peak on the SEC, with similar retention time as the Adalimumab-TNFa complex. In addition, earlier eluting protein peak is detected in the SEC, suggesting that Infliximab forms higher order complexes with TNFa.
Although the complexes Adalimumab-TNFa and Infliximab-TNFa have identical stoichiometry, the images of their classes were quite different and difficult to interpret [ Fig. S2(C,F) ]. The classes typically consisted of a central cluster of bright and dark domains. The central cluster of Adalimumab-TNFa was compact with one, two, or three bright domains and one or two dark spots. A pair of faint densities projected from the central cluster at a 1208 from each other. In contrast, the Infliximab-TNFa complexes consisted of a rectangular pair of four domains. Projecting from one side is a prominent bright density. A faint domain caps the ends of the central cluster. The faint domains in both complexes could represent the Fc domain (white asterisk).
Because the negative stain images of the 3:2 complex were difficult to interpret, we analyzed the Adalimumab-TNFa 3:2 complex by cryo electron microscopy. Initial attempts were hampered by aggregation of the complexes during the cryofreezing procedures (data not shown). Subsequent optimization by lowering the pH to 5.5 improved particle dispersion. A total of 18,269 particles were selected for class averaging and 100 classes were generated. However, they were mainly divided into two groups that displayed either 3-fold symmetry or a circular structure [ Fig. 3(A) ]. The lack of surrounding orientations of the complex results from very strongly preferred orientations. Nevertheless, a preliminary 3D model was generated which shows a density with a prominent 3-fold symmetric trigonal profile [ Fig. 3(B) ]. This density can be modeled as three Fab arms projecting from a central TNFa trimer [ Fig. 3(C,D) ], which resembles the trigonal plane and diamond shapes observed in the 2D class averages [ Fig. 3(A) ]. The 3D model from cryo-EM data fits well with the structural model that was generated by combining two sets of crystal structure of 3WD5, each consisting of one TNFa trimer and three Fab domains [ Fig. 3(C,D) ]. Although the Fc domains cannot be visualized in the EM data, the position of the Fc can be mapped to adjacent location of the Fab domains to depict the full length IgG in complex with TNFa [ Fig. 3(D) ].
Discussion
Development of effective treatments of chronic autoimmune diseases requires an understanding of how natural and engineered antibodies bind and neutralize cytokines and other effectors. By electron microscopy we demonstrate, for the first time, the higher order structure complex between a full length monoclonal antibody and a multivalent antigen. TNFa trimer contains three epitopes for antibody binding, leading to higher order complex such as 2:2 and 3:2 complex structures between antibody and antigen, as observed in our study. We also provide evidence that two mAbs, Adalimumab and Infliximab, form structurally different complexes with TNFa. The differences between the complexes arise directly from the binding site epitopes on TNFa. Although previous studies have shown the binding epitope of the Fab domains to TNFa and binding stoichiometry between the full length antibody to TNFa, 7, 8, 13 we have demonstrated for the first time the structural assembly of the full length antibody and TNFa using electron microscopy. The largest complex consists of two TNFa and three mAbs molecules. A 3:2 (antibody:antigen) complex can arise from the 2:2 complex by binding an additional mAb. This third mAb would bridge across the 2:2 complex and bind opposing pairs of TNFa (Fig. 2, red asterisk) . The 3:2 complex structures observed between antibody and TNFa is also in agreement with recent study using native-mass spectrometry and fluorescence-detected sedimentation velocity analytical ultracentrifugation analyses (FD-SV AUC). 13 The complete structure of 3:2 complex is depicted in Figure 4 by placing the Fc domain structure into the model. We hypothesize that 3:2 complex is the most stable complex between Adalimumab and TNFa because it is the major form present upon extended incubation and all binding epitopes on antibody and antigen are fully occupied. Interestingly, the stable complex was formed following slow equilibrium with larger higher order complexes or aggregates at the onset of the complex formation. 9 However, higher order complex or aggregates were observed in the complex of Infliximab-TNFa even after overnight incubation. This observation is also consistent with a similar study using FD-SV AUC analyses. 13 In summary, Adalimumab and Infliximab bind to different areas of TNFa and are seen the 2D projected images from negatively stained 2:2 complexes. Because of a strong preferred orientation of particles in ice, the cryoEM 3D volume of a 3:2 complex is at low resolution and limited to trigonal and circular shapes. We are optimizing our methods to yield random orientations that would improve the resolution of the structure.
Materials and Methods
Materials
Adalimumab was provided by AbbVie in a 67 g/L formulated solution. Infliximab (Janssen Biotech) was purchased in powder form and reconstituted according to the manufacturer's instructions. TNFa lyophilized powder was purchased from R&D System and reconstituted in phosphate buffer saline (PBS).
Sample preparation and electron microscopy
Adalimumab and Infliximab were each diluted in water or PBS for imaging of the IgG alone. For imaging of complexes, each IgG was mixed with TNFa, either in-solution or on-grid methods to generate different complexes of Adalimumab-TNFa and Infliximab-TNFa. In-solution incubation method was performed by mixing Adalimumab or Infliximab (each at 5 lg/ml final concentration) with TNFa (10 lg/ml final concentration) in a tube. After 15 min at room temperature an aliquot was applied directly onto a glow discharged 300 mesh copper grid covered with a carbon film, rinsed with water, and then negatively stained with 0.75% uranyl formate. Ongrid incubation was performed by applying 5 mL of Adalimumab or Infliximab (1 lg/mL) on a carbon grid and allowing for sample absorption for 30 s. Unbound IgGs were rinsed away with water and excess liquid was blotted with a filter paper. The grid was placed (sample side facing down) on a drop of TNFa (concentrations from 10 to 50 lg/mL) for 15 min. Unbound TNFa was rinsed off the grid with water and the grid was stained with drops of 0.75% uranyl formate.
For the formation of stable complexes, solutions of IgG (either Adalimumab or Infliximab) and TNFa were mixed to final concentration of 2 and 0.8 mg/ mL, respectively. 9 The mixtures were incubated at 378C overnight and analyzed on Superose 6 10/300 GL SEC column (GE Healthcare). Major eluted peaks [ Fig. 3 (A,D)] were manually collected for negative stain or cryo-EM imaging. For negative stain, 5 mL of fractionated sample was incubated for 30 s on a glow discharged copper grid covered with a continuous carbon film. The grid was blotted with a filter paper and washed twice briefly with water. Samples were stained by applying a drop of 0.75% uranyl formate on the grid for 45 s, blotted with filter paper, and air-dried.
For cryo-EM, the Adalimumab-TNFa complex was processed in a FEI Vitrobot Mark IV. A 4 mL sample from the fractionated complex mixture was applied onto a glow discharged R2/2 Quantifoil grid. After 1.5 s blotting time with filter paper in 100% humidity chamber, the grid was plunge-frozen in liquid ethane.
EM data collection and image processing
Image data for single particle images and tomography tilt series of negative-stained samples were collected on an FEI Tecnai T12 electron microscope operating at 120 keV equipped with 4k 3 4k CCD camera (Gatan Ultrascan).
Images for single particle analysis were recorded at a magnification of 67,000 (1.25Å /pixel), defocus 21.0 to 21.5lm and 110,000 (0.7Å /pixel), defocus 20.5 lm. Particles were selected manually, followed by 2D averaging classification by EMAN2 14 (see Table S1 for number of particles included in averaging analysis) Tomography tilt series were collected at magnification of 67,000, from 2608 to 1608 and images were recorded at every 28 degree under the control of FEI tomography software. The 10 nm colloidal gold fiducials were used to align micrographs using IMOD software. 15 Individual particles (120 particles for Adalimumab-TNF 2:2 complex and 198 particles for Infliximab-TNF 2:2 complex) in each tomograph were manually selected for subtomographic averaging in IMOD 15 (Table S1 ).
Cryo-EM samples were imaged with a Falcon II direct detector (4k 3 4k) and an FEI Titan Krios transmission electron microscope (NUS Cryo-EM facility). Single particle data were collected with Leginon software 16 at magnification of 47,000, pixel size 1.768 A8, defocus 3.5-5 lM, and electron dose of 20-25 e/Å 2 . Particles were manually selected and averaged into 2D classes to calculate initial 3D reconstructions by using EMAN2.
14 Structures resulted from single particle analysis and subtomography were superimposed or docked with the Chimera 17 and PyMOLl (The PyMOL Molecular Graphics System, Version 1.7 Schr€ odinger, LLC).
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